Nautilus Biotechnology Inc (NAUT) — Cash Flow-to-Debt Ratio
Nautilus Biotechnology Inc (NAUT) has a Cash Flow-to-Debt Ratio of -0.35x as of September 2025, meaning its operating cash flow of $-11.03 Million could theoretically repay 0% of its total liabilities ($31.78 Million) in one year. See NAUT financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nautilus Biotechnology Inc Cash Flow-to-Debt Ratio (2018–2024)
Historical debt coverage capacity for Nautilus Biotechnology Inc across 7 annual periods. For the full cash flow conversion analysis, see Nautilus Biotechnology Inc (NAUT) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for Nautilus Biotechnology Inc (2018–2024)
Year-by-year debt coverage analysis for Nautilus Biotechnology Inc. Check Nautilus Biotechnology Inc cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.74x | $-59.15 Million | $34.01 Million | ▼ -35.2% |
| 2023 | -1.29x | $-51.71 Million | $40.21 Million | ▲ +1.4% |
| 2022 | -1.30x | $-45.81 Million | $35.13 Million | ▼ -15.9% |
| 2021 | -1.13x | $-39.24 Million | $34.87 Million | ▼ -822.4% |
| 2020 | -0.12x | $-14.00 Million | $114.73 Million | ▲ +99.4% |
| 2019 | -19.72x | $-9.66 Million | $490.00K | ▼ -1065.2% |
| 2018 | -1.69x | $-238.30 Million | $140.82 Million | — |